Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Inclusion Criteria: * locally advanced or metastatic NSCLC that has progressed during or following therapy with an ALK inhibitor * tumor must carry an ALK rearrangement in 15% or more of tumor cells as measured by FISH * disease that can be evaluated by RECIST v1.1 and measurable disease Exclusion Criteria: * central nervous system (CNS) metastases that are symptomatic or require increasing steroids or CNS-directed therapy to control CNS disease * history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis * clinically significant cardiac dysfunction * inadequate end organ function as defined by specified laboratory values * use of medications known to be strong inhibitors or inducters of CYP3A4/5 that cannot be discontinued at least 1 week prior to start of treatment * use of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be discontinued at least 1 week prior to start of treatment * clinically significant, uncontrolled impaired gastrointestinal function or GI disease * prior treatment with a HSP90 inhibitor * radiotherapy to lung within 4 weeks prior to the first dose of study treatment or patients who have not recovered from radiotherapy-related toxicities * pregnant or nursing women * history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.